ClinicalTrials.gg

Program

MRNA-1283

A development code. Also written as “mRNA-1283”, “mRNA-1283.251 Variant-containing Formulation” and “mRNA-1283.222”.

Its studies are mostly in COVID-19 · Coronavirus Infections, led by Moderna.

Furthest: phase 4, since Jul 21, 20257 company-led studies, 3 open or runningNext primary completion: Dec 11, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna73 open or runningphase 4since Jul 21, 2025Mar 22, 2021Dec 11, 2026phase 4 · NCT07863635

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2021First study: phase 1 study in Coronavirus InfectionsFirst studyNCT04813796 · 104 enrolled · United States
  2. Nov 24, 2021Phase 2 study in Coronavirus InfectionsNCT05137236 · 540 enrolled · United States
  3. Apr 13, 2023Phase 3 study in COVID-19NCT05815498 · 13,553 enrolled · United States, Canada, Japan and more
  4. Jul 21, 2025Phase 4 study in COVID-19NCT07089706 · 832 enrolled · United States
  5. Nov 25, 2025Phase 4 study in Coronavirus InfectionsNCT07266558 · 30,000 enrolled · United States
  6. Sep 2, 2026Phase 2 study in Coronavirus InfectionsNCT07808697 · 300 planned · United States, Argentina, Dominican Republic and more
  7. Oct 2, 2026Phase 4 study in Coronavirus InfectionsNCT07863635 · 600 planned · United States

Ahead

  1. Dec 11, 2026Primary completion: phase 4 study in Coronavirus InfectionsNCT07863635
  2. Jun 16, 2027Primary completion: phase 4 study in Coronavirus InfectionsNCT07266558
  3. Aug 30, 2029Primary completion: phase 2 study in Coronavirus InfectionsNCT07808697

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07863635Coronavirus Infections · United States4RecruitingDec 11, 2026600
NCT07808697Coronavirus Infections · United States, Argentina, Dominican Republic and more2RecruitingAug 30, 2029300
NCT07266558Coronavirus Infections · United States4Active, not recruitingJun 16, 202730,000
NCT07089706COVID-19 · United States4CompletedJun 16, 2026832
NCT05815498COVID-19 · United States, Canada, Japan and more3CompletedApr 12, 202513,553
NCT05137236Coronavirus Infections · United States2CompletedMar 23, 2023540
NCT04813796Coronavirus Infections · United States1CompletedJul 25, 2023104

How it is read

Names in the registry

  • “mRNA-1283”, 5 entries
  • “mRNA-1283.251 Variant-containing Formulation”, 1 entry
  • “mRNA-1283.222”, 1 entry
  • “mRNA-1283.815”, 1 entry
  • “mRNA-1283.211”, 1 entry

Codes read as this program: MRNA1283.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.